Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

利比韦林 医学 打开标签 替诺福韦 杜鲁特格拉维尔 恩曲他滨 人类免疫缺陷病毒(HIV) 内科学 临床试验 病毒载量 抗逆转录病毒疗法 病毒学
作者
Hans Jaeger,Edgar Turner Overton,Gary J. Richmond,Giuliano Rizzardini,Jaime Federico Andrade-Villanueva,Rosie Mngqibisa,Antonio Ocampo Hermida,Anders Thalme,Elena Belonosova,Faïza Ajana,Paul D. Benn,Yuanyuan Wang,Krischan J Hudson,Carlos Martín Español,Susan L. Ford,Herta M. Crauwels,David A. Margolis,Christine L. Talarico,Kimberly Y. Smith,Veerle Van Eygen
出处
期刊:The Lancet HIV [Elsevier BV]
卷期号:8 (11): e679-e689 被引量:146
标识
DOI:10.1016/s2352-3018(21)00185-5
摘要

Background Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-2M week 48 results showed non-inferiority of long-acting cabotegravir and rilpivirine administered every 8 weeks compared with that of every 4 weeks. In this study, we report the efficacy, safety, and tolerability results from the week 96 analysis. Methods ATLAS-2M is a randomised, multicentre, open-label, phase 3b, non-inferiority trial conducted in 13 countries, evaluating the safety and efficacy of maintenance treatment with intramuscular injections of long-acting cabotegravir and rilpivirine, administered every 8 weeks versus every 4 weeks, to people living with HIV-1. Virologically suppressed adults with HIV-1, either already receiving intramuscular long-acting cabotegravir and rilpivirine every 4 weeks (ie, ATLAS study rollover participants) or oral standard of care, were randomly assigned (1:1), in an unblinded fashion, to receive either intramuscular long-acting cabotegravir (600 mg) and rilpivirine (900 mg) every 8 weeks (ie, the every 8-week dosing group) or intramuscular long-acting cabotegravir (400 mg) and rilpivirine (600 mg) every 4 weeks (ie, the every 4-week dosing group). Randomisation was generated using the GlaxoSmithKline-validated randomisation software RANDALL NG (version 1.3.3). The primary endpoint at week 48 was the proportion of participants with plasma HIV-1 RNA measurements of 50 copies per mL or more (ie, the US Food and Drug Administration [FDA] Snapshot algorithm), which has been published previously. Here, we present the week 96 results: the proportion of participants with plasma HIV-1 RNA measurements of less than 50 copies per mL (FDA Snapshot algorithm), with a non-inferiority margin of −10%; the proportion of participants with plasma HIV-1 RNA measurements of 50 copies per mL or more (FDA Snapshot algorithm), with a non-inferiority margin of 4%; the proportion of participants with protocol-defined confirmed virological failure (ie, two consecutive plasma HIV-1 RNA measurements ≥200 copies per mL); safety; pharmacokinetics; and tolerability. This study is registered with ClinicalTrials.gov, number NCT03299049, and is currently ongoing. Findings Between Oct 27, 2017, and May 31, 2018, a total of 1149 participants were screened; of whom, 1049 (91%) were randomly assigned and 1045 (91%) initiated treatment (522 in the every 8-week dosing group and 523 in the every 4-week dosing group). The median age was 42 years (IQR 34–50). 280 (27%) of 1045 participants were assigned female at birth and 764 (73%) were white. At week 96 (FDA Snapshot algorithm), 11 (2%) of 522 participants in the every 8-week dosing group and six (1%) of 523 in the every 4-week dosing group had an HIV-1 RNA measurement of 50 copies per mL or more, with an adjusted treatment difference of 1·0 (95% CI −0·6 to 2·5), meeting the prespecified non-inferiority threshold of 4%; 475 (91%) of 522 participants in the every 8-week dosing group and 472 (90%) of 523 in the every 4-week dosing group maintained an HIV-1 RNA measurement of less than 50 copies per mL, with an adjusted treatment difference of 0·8 (95% CI −2·8 to 4·3), which met the prespecified non-inferiority threshold of −10%. One participant in the every 8-week dosing group met the confirmed virological failure criterion since the week 48 analysis at week 88, resulting in a total of nine participants in the every 8-week dosing group and two in the every 4-week dosing group having confirmed virological failure. No new safety signals were identified, and no treatment-related deaths occurred. Injection site reactions were the most common adverse event, occurring in 412 (79%) of 522 participants in the every 8-week dosing group and 400 (76%) of 523 in the every 4-week dosing group. Most injection site reactions were grade 1 or 2 (7453 [99%] of 7557 in both groups), with a median duration of 3 days (IQR 2–5). Interpretation Long-acting cabotegravir and rilpivirine dosed every 8 weeks had non-inferior efficacy compared with that of every 4 weeks through the 96-week analysis, with both regimens maintaining high levels of virological suppression. These results show the durable safety, efficacy, and acceptability of dosing long-acting cabotegravir and rilpivirine monthly and every 2 months as maintenance therapy for people living with HIV-1. Funding ViiV Healthcare and Janssen Research & Development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zzh_zxc完成签到,获得积分10
2秒前
3秒前
李爱国的应助被richardhipower采纳,获得10
5秒前
6秒前
Hello的应助被TT采纳,获得10
8秒前
望禾完成签到,获得积分10
8秒前
XX完成签到,获得积分10
11秒前
12秒前
handsomeboy完成签到,获得积分10
13秒前
15秒前
137292967发布了新的文献求助10
16秒前
张磊发布了新的文献求助10
16秒前
16秒前
FashionBoy的应助被richardhipower采纳,获得10
16秒前
田様的应助被Cylara采纳,获得10
18秒前
可爱的函函的应助被yuyuyu采纳,获得10
18秒前
19秒前
无助的考拉完成签到,获得积分10
19秒前
19秒前
19秒前
张张发布了新的文献求助10
20秒前
21秒前
K9999K发布了新的文献求助10
21秒前
Lydia发布了新的文献求助10
21秒前
在水一方的应助被zww采纳,获得10
22秒前
华仔的应助被科研通管家采纳,获得10
22秒前
科目三的应助被科研通管家采纳,获得10
22秒前
烟花的应助被科研通管家采纳,获得10
23秒前
秋风的应助被科研通管家采纳,获得10
23秒前
打打的应助被科研通管家采纳,获得30
23秒前
科研通AI2S的应助被科研通管家采纳,获得10
23秒前
隐形曼青的应助被科研通管家采纳,获得10
23秒前
852的应助被科研通管家采纳,获得10
23秒前
领导范儿的应助被科研通管家采纳,获得10
23秒前
生煎包完成签到,获得积分10
23秒前
完美世界的应助被科研通管家采纳,获得10
23秒前
CAOHOU的应助被科研通管家采纳,获得10
24秒前
今后的应助被科研通管家采纳,获得10
24秒前
Julian的应助被时尚凝海采纳,获得30
24秒前
顺顺利利的应助被科研通管家采纳,获得10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192604
求助须知:如何正确求助?哪些是违规求助? 9579105
关于积分的说明 21863529
捐赠科研通 7792211
什么是DOI,文献DOI怎么找? 3436974
关于科研通互助平台的介绍 2560633
邀请新用户注册赠送积分活动 2483864